Guillem Laporta joins Ysios Capital as Principal after 5 years at Edmond de Rothschild group, Paris.

Ysios is also incorporating two new Venture Partners; Lance Berman and Claudia D’Augusta.

These key additions will strengthen Ysios Capital team which is now focused on divesting its first fund, closing last investments of its second fund and preparing for raising its third fund.

Barcelona, September 24, 2018 – Ysios Capital, a leading biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’Augusta.

Guillem will be responsible for sourcing and evaluating investment opportunities. As a Principal he will also represent Ysios as member of the board of its portfolio companies.

Guillem is a CFA charterholder and holds a bachelor’s degree in Biotechnology from the Universitat Autonoma de Barcelona and a bachelor’s degree in Business Administration from the Universitat Pompeu Fabra. Previously, Guillem was Associate at Edmond de Rothschild group (now Andera Partners). Before joining Edmond de Rothschild group in 2013, Guillem started his career at Caixa Capital Risc, in the life sciences team.

“We have known Guillem for a long time and are very pleased he now has joined our team. His experience will be very valuable in helping us continue to invest in promising life sciences companies developing truly differentiated drugs for unmet medical needs”, commented Joël Jean-Mairet, Managing Partner at Ysios.

The Ysios team has also been reinforced with two new part time Venture Partners that will bring strong networks, in-depth industry knowledge and proven experience in key focus areas of Ysios: Claudia D’Augusta, currently General Manager at TiGenix, with extensive experience in the financial management of biotechnology companies, and Lance Berman, medical doctor and independent consultant, who had previously been Chief Medical Officer at various companies.

Claudia holds a bachelor’s degree in Economics and a PhD in Business Administration and Finance from Bocconi University, Italy. She is General Manager at TiGenix (now Takeda) since June 2018. Since 2011 Claudia was Chief Financial Officer of TiGenix leading the Company’s IPO on Nasdaq in 2016, being a member of the Executive Committee and responsible for Finance, Legal and Investor Relations. Since June 2018, she is observer on the board of Ysios’ portfolio company CVRx (United States).

Lance received his Bachelor of Medicine and Bachelor of Surgery degree from the University of Cape Town, South Africa and holds a MSc (Pharmaceutical Medicine). Prior to joining Ysios, Lance was Chief Medical Officer and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the Company’s clinical development, medical affairs and drug safety functions; as well as playing a key role in the preparation and execution of the Company’s fund-raising initiatives including the Company’s IPO. Under his clinical leadership, the Company secured FDA and EMA approval for Veltassa®. In addition to having worked across multiple therapeutic areas in clinical development, he has also worked closely with commercial teams to secure product reimbursement and to plan and execute product launches. He is currently an independent consultant. Since July 2018, he serves on the board of Ysios’ portfolio company Oxthera (Sweden).

About Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital currently manages about €200M ($220M) distributed across two funds: Ysios BioFund I, fully invested, and Ysios BioFund II Innvierte.

More information on:www.ysioscapital.com